TransCode Therapeutics启动针对ctDNA阳性结直肠癌患者的TTX-MC138二期a临床试验

美股速递
May 27

TransCode Therapeutics公司已启动一项二期a阶段临床试验,该试验旨在评估其候选药物TTX-MC138在循环肿瘤DNA(ctDNA)阳性的结直肠癌患者中的疗效与安全性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10